603301 振德医疗
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入3,184,2601.88%4,263,8864,127,0446,137,6345,091,572
减:营业总成本2,957,6024.38%3,861,7803,740,2785,246,6114,356,103
    其中:营业成本2,103,7743.31%2,813,3642,694,6113,991,5053,319,139
               财务费用26,09494.87%(17,551)(20,798)2,07327,165
               资产减值损失(13,174)-49.58%(41,817)(207,460)(75,560)(36,072)
公允价值变动收益2,716-193.15%(12,246)(21,065)(11,220)(2,704)
投资收益8,488-1.01%11,0736,801(59,842)36,736
    其中:对联营企业和合营企业的投资收益(1,988)449.09%(827)(632)(2,196)(302)
营业利润249,724-36.92%491,796225,948812,810821,973
利润总额248,829-34.66%475,459218,892801,716819,949
减:所得税费用38,285-39.56%78,2485,49299,95999,002
净利润210,544-33.68%397,211213,400701,758720,947
减:非控股权益7,358-26.53%12,04015,00121,879125,085
股东净利润203,186-33.91%385,171198,399679,878595,862

市场价值指针
每股收益 (元) *0.760-33.91%1.4500.7402.8702.640
每股派息 (元) *----0.6501.2500.7500.600
每股净资产 (元) *21.4032.17%21.17920.13720.79817.899
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容